O P S C S 25 AR 25 205 S S

Reply to Missing Parts under 37 CFR 1.52 or 1.53

A 100

D. Peter Hochberg Co., L.P.A.

Firm Name

PTO/SB/21 (09-04)
Approved for use through 07/31/2006, OMB 0651-0031

•	\$ JUSS,
PTO/SB/21 (09-04) 7/31/2006. OMB 0651-0031 RTMENT OF COMMERCE	/IFW

Merthe Paperwork Reduction Act of 1	es no nersor				 Office; U.S. DEPARTMENT OF COMMERC unless if displays a valid OMB control number
		Application Number	_	05,31	
TRANSMITTAL		Filing Date	Ť-		
FORM		First Named Inventor	Tina	Rade	macher
		Art Unit	1615		
(to be used for all correspondence after ini	ial filing)	Examiner Name			
Total Number of Pages in This Submission		Attorney Docket Number	R008	61US	- 90568
	ENC	LOSURES (Check all	that apply)	
X Fee Transmittal Form		Drawing(s)			After Allowance Communication to TC
X Fee Attached (\$130.		Licensing-related Papers			Appeal Communication to Board of Appeals and Interferences
(CREDIT CARD FORM) Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement (SUPPLEMENTAL)		Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD	ddress	Ltr re Filing	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Card receipt erroneous issuance of Rept; Combined Dec. & //fee; Ltr w/IPER in English
Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application	overp	e charge any add	itiona ant's	l fee attor	es or credit any rney's Deposit Account

0.5	1/100/dl				_
Printed name	D. Peter Hochberg	-			
Date	4 / 20 / 2005	Reg. No.	24,603		_
	CERTIFICATE OF	TRANSMISSION/MAIL	LING		`
	at this correspondence is béing facsimile transm as first class mail in an envelope addressed to: elow:				_
Signature	Christine Kolra	IN .			
Typed or printed n	ame Christine Kotran	•	Date	4 / 20. / 2005	ز

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/17 (12-04) Approved for use through 07/31/2006. OMB 0651-0032

Under the Renerwork Reduction	n Act of 1995	no persons are required	to respond to	J.S. Patent and Tra a collection of infor	demark Office; U.S. DEP/ mation unless it displays a	ARTMENT OF COMMERCE a valid OMB control number
Effecti Feet Suant to the Consolida	ve on 12/08/2	004.			Complete if Knowr	
				ation Number	10/505,317	
		MITTAL	= Filing (Date		
For	· FY 2	005	First N	amed Inventor	TINA RADEMAC	CHER
Applicant claims small	entity etatue	See 37 CED 1 27	Exami	ner Name		
		· · · · · · · · · · · · · · · · · · ·	Art Un	t	1615	
TOTAL AMOUNT OF PAYA	MENT (\$)		Attorne	y Docket No.	R00861US - 9	90568
METHOD OF PAYMENT	(check all	that apply)				
Check X Credit C		Money Order		-		
X Deposit Account De	posit Accoun	t Number: 08-244	1	Deposit Account Na	_{ame:} D. Peter I	Hochberg Co., LP/
For the above-identifi	ied deposit	account, the Director is	hereby auth	orized to: (check	all that apply)	
Charge fee(s)	indicated be	elow		Charge fee(s)	indicated below, exce	ept for the filing fee
χ Charge any ac	ditional fee	(s) or underpayments of	of fee(s)	Credit any ov	erpayments	
WARNING: Information on this	form may be	1/ ecome public. Credit can	_			vide credit card
information and authorization	on PTO-2038					
FEE CALCULATION		·····				
1. BASIC FILING, SEAR	CH, AND I FILING I		ES EARCH FEI	EC EVAL	AINIATIONI EEEO	
Anatharian Tona	S	mall Entity	Small	Entity	MINATION FEES Small Entity	
Application Type	Fee (\$)		e(\$) Fee			Fees Paid (\$)
' Utility	300		00 25			
Design	200		00 50			
Plant	200		00 15			
Reissue	300		00 25		200	
Provisional 2. EXCESS CLAIM FEES	200	100	0) (0	
Fee Description Each claim over 20 or, for	Reissues,					Small Entity Fee (\$) Fee (\$) 50 25
Each independent claim of Multiple dependent claims	ver 3 or, fo	or Reissues, each inc	dependent o	laim more thar	n in the original pate	
	s xtra Claims	s Fee (\$) F	ee Paid (\$)	Multir	ole Dependent Claims	360 180
20 or HP =		x=			e (\$) Fee Pai	
HP = highest number of total cl Indep. Claims E	xtra Claims		ee Paid (\$)			
HP = highest number of indepe						
3. APPLICATION SIZE F If the specification and of for each additional 5 Total Sheets 100 =	drawings e 0 sheets or Extra Shee	r fraction thereof. So	ee 35 U.S.(each additio		and 37 CFR 1.16(s) on thereof Fee (\$)	
4. OTHER FEE(S) Non-English Specific						Fees Paid (\$)
Other: LATE FILI					_	130.00

SUBMITTED BY Registration No. Signature Telephone 216-771-3800 24,603 (Attorney/Agent) D. Peter Hochberg Date Name (Print/Type) / 10 2005

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

licant

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Tina Rademacher et al.

Serial No.

10/505,317 / Conf. No. 5171

Filed

I.A. date: 02/04/2003 / Priority date: 02/21/2002

Title

FILM-SHAPED OR WAFER-SHAPED PHARMACEUTICAL

PREPARATION WITH MASKED TASTE (per Prelim. Amd.

mld. 8/20/2004)

Examiner

Art Unit :

1615

Attorney Docket:

RO0861US (#90568)

LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Enclosed for the records of the USPTO is a copy of the English translation of the International Preliminary Examination Report for PCT/EP2003/001052.

Respectfully submitted,

DPH/SM/ck

Enc.

D. Peter Hochberg Reg. No. 24,603

D. Peter Hochberg Co., L.P.A. 1940 East Sixth Street - 6th Floor Cleveland, OH 44114 (216) 771-3800

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being deposited with the United States Postal Service as first class mail in an envelope addressed: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Christine A. Kotran

PATENT COOPERATION TREATY



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

International application No. PCT/EP2003/001052 International filing date (day/month/year) O4 February 2003 (04.02.2003) International Patent Classification (IPC) or national classification and IPC A61K 9/70 Applicant LTS LOHMANN THERAPIE-SYSTEME AG 1. This international preliminary examination report has been prepared by this International Preliminary Examinatory Application 1. This international preliminary examination report has been prepared by this International Preliminary Examinatory Application 2. This international preliminary examination report has been prepared by this International Preliminary Examinatory Application 2. This international preliminary examination report has been prepared by this International Preliminary Examinatory Application 2. This international preliminary examination report has been prepared by this International Preliminary Examinatory Application 3. This international preliminary examination report has been prepared by this International Preliminary Examinatory 1. This international preliminary examination report has been prepared by this International Preliminary Examination Preliminary Examin	02.2002)
International Patent Classification (IPC) or national classification and IPC A61K 9/70 Applicant LTS LOHMANN THERAPIE-SYSTEME AG 1. This international preliminary examination report has been prepared by this International Preliminary Examination.	nining
LTS LOHMANN THERAPIE-SYSTEME AG 1. This international preliminary examination report has been prepared by this International Preliminary Examination. For the prepared by this International Preliminary Examination.	
1. This international preliminary examination report has been prepared by this International Preliminary Exam	
Authority and is transmitted to the applicant according to Article 36. 2. This REPORT consists of a total of	ch have uthority
These annexes consist of a total of 7 sheets.	
3. This report contains indications relating to the following items:	
Basis of the report	
II Priority	
III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	
IV Lack of unity of invention	
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applications and explanations supporting such statement	ability;
VI Certain documents cited	ĺ
VII Certain defects in the international application	l
VIII Certain observations on the international application	
Date of submission of the demand Date of completion of this report	
08 May 2003 (08.05.2003) 13 April 2004 (13.04.2004)	
Name and mailing address of the IPEA/EP Authorized officer	
Facsimile No. Telephone No.	i

Form PCT/IPEA/409 (cover sheet) (January 1994)

Translation

International application No.

PCT/EP2003/001052

I. Basis of th	ie report		
1. This report	t has been drawn the 14 are referred to	on the basis of (Replacement sheet in this report as "originally filed"	s which have been furnished to the receiving Office in response to an invitation and are not annexed to the report since they do not contain amendments.):
	the international	application as originally filed.	
\boxtimes	the description,	pages1-19	_, as originally filed,
		pages	_, filed with the demand,
		pages	, filed with the letter of,
		pages	, filed with the letter of
\boxtimes	the claims,	Nos	, as originally filed,
		Nos.	, as amended under Article 19,
		Nos	, filed with the demand,
		Nos. <u>1-26</u>	, filed with the letter of 27 September 2003 (27.09.2003) ,
		Nos.	, filed with the letter of
	the drawings,	sheets/fig	, as originally filed,
		sheets/fig	, filed with the demand,
		sheets/fig	, filed with the letter of,
	ı		, filed with the letter of
2. The amend	ments have resulte	ed in the cancellation of:	
	the description,	pages	
· 🔲	the claims,	Nos.	
	the drawings,	sheets/fig	
3. L to go	report has been es beyond the disclo	tablished as if (some of) the ame sure as filed, as indicated in the	endments had not been made, since they have been considered Supplemental Box (Rule 70.2(c)).
4. Additional	observations, if ne	cessary:	
			·

International application No. PCT/EP 03/01052

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: III.1

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 22-26 relate to subject matter which this Authority considers to fall under PCT Rule 67.1(iv). Consequently, no opinion is established with regard to the industrial applicability of the subject matter of these claims (PCT Article 34(4)(a)(i)).

International application No.
PCT/EP 03/01052

v.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
	citations and explanations supporting such statement

Statement			
Novelty (N)	Claims	15, 16, 18	YES
	Claims	1-14, 17, 19-26	NO
Inventive step (IS)	Claims		YES
	Claims	1-26	NO
Industrial applicability (IA)	Claims	1-21	YES
	Claims		NO NO

- 2. Citations and explanations
 - 1. Reference is made to the following document: D1: US-A-2001/0006677.
 - 2. Novelty (PCT Article 33(2))

The present application does not comply with the requirements of PCT Article 33(2), because the subject matter of claims 1-14, 17 and 19-26 is not novel.

Film or wafer-type effervescent medicinal preparations are already known from D1 (see D1, columns 51, 56, 57 and 85, and the examples). It is clear from the dependent claims of the present application, as well from the scope of claim 1, that the "gas-forming component" could be an effervescent mixture.

The subject matter of claims 1-14, 17 and 19-26 is therefore novel.

3. Inventive step (PCT Article 33(3))

Document D1 can be considered to be of particular relevance as regards inventive step (PCT Article 33(3)). That document in fact solves the same problem as the present

International application No. PCT/EP 03/01052

application. The subject matter of claims 15 and 18 cannot be considered to be inventive.

Consequently, so far as novel subjects as per the invention are affected, the present application obviously does not comply with the requirements of PCT Article 33(3) in relation to that document, which discloses the prior art.

4. The PCT Contracting States do not have uniform criteria for assessing the industrial applicability of claims 22-26 in their present form. Patentability may also depend on the wording of the claims. The EPO, for example, does not recognize the industrial applicability of claims to the medical use of a compound; it may, however, allow claims to the first medical application of a known compound or to the use of such a compound in the manufacture of a drug for a new medical application.